Company intelligence / Profile preview

Santen Ventures

Emeryville, California, United States

Ownership: Private
Development stage: Other

Overview

Santen Ventures invests globally in drug-discovery and early clinical stage ophthalmic innovations to accelerate development in eye health, including retinal, glaucoma, dry eye, corneal, refractive disorders, novel delivery/devices, gene/cell therapies, and digital health tools[1].

Therapeutic areas: Ophthalmology
Modalities: Small moleculeGene therapyCell therapyMonoclonal antibodyBiologicDevicePeptidesDigital health tools
Industry: Investors

Partnerships

PeptiDream (peptide therapies for ophthalmic diseases)twoXAR (AI-driven glaucoma drug candidates)RIKEN/Foundation for Biomedical Research and Innovation (iPSC-based therapy research)University College London (ophthalmology research)[3]Verily (joint venture for eye health)[6]

Beyond the preview

Go deeper on Santen Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Santen Ventures.

Explore the full profile